Zhaoke Ophthalmology (HKG:6622) shrank its attributable loss for the year 2024 to 237.5 million yuan from 385 million yuan in the year-ago period, a Monday filing with the Hong Kong bourse said.
Loss per share stood at 0.43 yuan, down from 0.71 yuan in the corresponding period last year.
The ophthalmic pharmaceutical company's revenue for the year increased to 69.3 million yuan from 18.8 million yuan a year prior, mainly due to a rise in licensing income.
The firm attributed the lower loss mainly to a milestone payment received under a product license agreement, significant sales growth in key ophthalmic drug products, and lower R&D expenses.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。